AU661017B2 - N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present - Google Patents

N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present

Info

Publication number
AU661017B2
AU661017B2 AU22868/92A AU2286892A AU661017B2 AU 661017 B2 AU661017 B2 AU 661017B2 AU 22868/92 A AU22868/92 A AU 22868/92A AU 2286892 A AU2286892 A AU 2286892A AU 661017 B2 AU661017 B2 AU 661017B2
Authority
AU
Australia
Prior art keywords
preparation
present
pharmaceutical compositions
substituted heterocyclic
heterocyclic derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22868/92A
Other languages
English (en)
Other versions
AU2286892A (en
Inventor
Claude Muneaux
Yvette Muneaux
Pierre Perreaut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elf Sanofi SA
Original Assignee
Elf Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elf Sanofi SA filed Critical Elf Sanofi SA
Publication of AU2286892A publication Critical patent/AU2286892A/en
Application granted granted Critical
Publication of AU661017B2 publication Critical patent/AU661017B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AU22868/92A 1991-09-10 1992-09-10 N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present Ceased AU661017B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9111161A FR2681067B1 (fr) 1991-09-10 1991-09-10 Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
FR9111161 1991-09-10

Publications (2)

Publication Number Publication Date
AU2286892A AU2286892A (en) 1993-03-11
AU661017B2 true AU661017B2 (en) 1995-07-13

Family

ID=9416798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22868/92A Ceased AU661017B2 (en) 1991-09-10 1992-09-10 N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present

Country Status (19)

Country Link
EP (1) EP0532410A1 (fr)
JP (1) JPH05213894A (fr)
KR (1) KR930006008A (fr)
AU (1) AU661017B2 (fr)
CA (1) CA2077967A1 (fr)
CZ (1) CZ275992A3 (fr)
FR (1) FR2681067B1 (fr)
HU (1) HUT63616A (fr)
IL (1) IL103116A (fr)
LT (1) LT3148B (fr)
LV (1) LV10255B (fr)
MX (1) MX9205155A (fr)
MY (1) MY108089A (fr)
NO (1) NO180678C (fr)
NZ (1) NZ244258A (fr)
PL (1) PL171524B1 (fr)
RU (1) RU2107062C1 (fr)
TW (1) TW218871B (fr)
ZA (1) ZA926899B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131021T2 (de) * 1990-12-14 1999-08-12 Smithkline Beecham Corp Angiotensin-ii-rezeptor blockierende zusammensetzungen
US5484939A (en) * 1993-03-12 1996-01-16 Lonza Ltd. 2-substituted 5-chlorimidazoles
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
HU218681B (hu) 1997-07-25 2000-10-30 Sanofi-Synthelabo Eljárás 1,3-diaza-spiro(4,4)non-1-én-4-on-származékok előállitására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek
HU218680B (hu) 1997-07-25 2000-10-30 Sanofi-Synthelabo Eljárás 1,3-diaza-spiro[4,4]non-1-én-4-on-származékok előállítására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek
AU767456B2 (en) 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
BRPI0406987A (pt) 2003-01-31 2006-01-10 Sankyo Co Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
AP2007004161A0 (en) * 2005-04-28 2007-10-31 Pfizer Ltd Amino acid derivatives
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3239170B1 (fr) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6463190A (en) * 1987-08-17 1991-03-14 American Cyanamid Company Intermediate compounds in the preparation of benzenesulfonyl carboxamide compounds and benzenesulfonyl-2- imidazolin-5-one compounds and methods of preparation thereof
AU8375591A (en) * 1990-09-10 1992-03-12 Ciba-Geigy Ag Azacyclic compounds
AU646343B2 (en) * 1991-06-27 1994-02-17 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH540271A (de) 1970-05-29 1973-08-15 Agripat Sa Verfahren zur Herstellung neuer, herbizid wirksamer s-Triazine und deren Verwendung zur Bekämpfung von Unkräutern
US4017510A (en) 1975-11-12 1977-04-12 American Cyanamid Company Imidazoisoindolediones and the use thereof as herbicidal agents
DE3545597A1 (de) * 1985-12-21 1987-07-02 Celamerck Gmbh & Co Kg Neue herbizid wirksame imidazolinone
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2020073A1 (fr) * 1989-07-03 1991-01-04 Eric E. Allen Quinazolinones substitues comme antagonistes de l'angiotensine ii
DE69024556T2 (de) * 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
JP2004247578A (ja) 2003-02-14 2004-09-02 Kawasaki Microelectronics Kk 半導体装置および半導体装置の製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6463190A (en) * 1987-08-17 1991-03-14 American Cyanamid Company Intermediate compounds in the preparation of benzenesulfonyl carboxamide compounds and benzenesulfonyl-2- imidazolin-5-one compounds and methods of preparation thereof
AU8375591A (en) * 1990-09-10 1992-03-12 Ciba-Geigy Ag Azacyclic compounds
AU646343B2 (en) * 1991-06-27 1994-02-17 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
NO180678B (no) 1997-02-17
MY108089A (en) 1996-08-15
LTIP119A (en) 1994-07-15
NO923509L (no) 1993-03-11
PL171524B1 (pl) 1997-05-30
ZA926899B (en) 1993-03-16
HUT63616A (en) 1993-09-28
RU2107062C1 (ru) 1998-03-20
CZ275992A3 (en) 1993-03-17
JPH05213894A (ja) 1993-08-24
AU2286892A (en) 1993-03-11
NO180678C (no) 1997-05-28
MX9205155A (es) 1993-03-01
FR2681067B1 (fr) 1993-12-17
NO923509D0 (no) 1992-09-09
PL295874A1 (en) 1993-04-19
TW218871B (fr) 1994-01-11
CA2077967A1 (fr) 1993-03-11
KR930006008A (ko) 1993-04-20
LV10255B (en) 1995-04-20
IL103116A (en) 1998-04-05
NZ244258A (en) 1996-10-28
FR2681067A1 (fr) 1993-03-12
LT3148B (en) 1995-01-31
IL103116A0 (en) 1993-02-21
HU9202889D0 (en) 1992-11-30
EP0532410A1 (fr) 1993-03-17
LV10255A (lv) 1994-10-20

Similar Documents

Publication Publication Date Title
ZA945656B (en) 1-Benzenesfulfonyl-1,3-dihydro-indol-2-one derivatives their preparation and pharmaceutical compositions in which they are present
IL111314A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL111002A0 (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
IL99225A0 (en) 3-amidopyrazole derivatives,their preparation and pharmaceutical compositions containing them
IL109234A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL101864A0 (en) Thiopyranopyrrole derivatives,their preparation and pharmaceutical compositions containing them
IL105412A0 (en) Indole derivatives,their preparation and pharmaceutical compositions containing them
IL110481A0 (en) 1-Benzenesulfonyl-1,3-dihydro-2h-benzimidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them
IL100262A0 (en) Alpha-oxoacetamide derivatives,their preparation and pharmaceutical compositions containing them
IL108859A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
NZ243206A (en) Thiazole derivatives, preparation and pharmaceutical compositions thereof
IL111533A0 (en) Quinoxalinedione derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
AU661017B2 (en) N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IL97050A0 (en) 4-isoxazolecarboxamide derivatives,pharmaceutical compositions containing them and their preparation
IL111294A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL110980A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL112097A0 (en) Indoline derivatives, their preparation and pharmaceutical compositions containing them
IL98542A0 (en) Benzoquinazoline derivatives,their preparation and pharmaceutical compositions containing them
IL108636A0 (en) Polysubstitued 2-amino-thiazole derivatives, their preparation and pharmaceutical compositions containing them
IL108703A0 (en) Substituted azolone derivatives, their preparation and pharmaceutical compositions containing them
IL109073A0 (en) Amidine derivatives, their preparation and pharmaceutical compositions containing them
IL108800A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
IL102500A0 (en) 3-deoxy-mannosamine derivatives,their preparation and pharmaceutical compositions containing them
IL109751A0 (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
AU8146994A (en) Novel taxicine derivatives, their preparation and pharmaceutical compositions containing them